Experience

Davis Polk advised the initial purchasers in connection with a $300 million Regulation S offering by CIFI Holdings (Group) Co. Ltd. of its 5.950% senior notes due 2025. Established in 2000…

Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $200 million 8.300% senior notes due 2023. Zhenro Properties Group…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $200 million 8.350% senior notes due 2024. Concurrently with the…

Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…

Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $200 million 5.6% senior notes due 2021. Zhenro Properties Group…

Davis Polk advised Zai Lab Limited in connection with its follow-on offering of approximately $300 million of American depositary shares, representing 5,500,000 ordinary shares by the…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Dexin China Holdings Company Limited of $200 million 11.875% senior notes due 2022. Dexin China…